U.S. Approves First Three COVID Vaccine Injury Claims — And Pays Out a Total of $4,634.89

The Health and Resources Service Administration approved its first three payments to people injured by COVID-19 vaccines — one for anaphylaxis and two for myocarditis — amounting to a total of $4,634.89.

All Global Research articles can be read in 51 languages by activating the Translate Website button below the author’s name.

To receive Global Research’s Daily Newsletter (selected articles), click here.

Click the share button above to email/forward this article to your friends and colleagues. Follow us on Instagram and Twitter and subscribe to our Telegram Channel. Feel free to repost and share widely Global Research articles.

*** 

The U.S. government approved its first three payments to people injured by COVID-19 vaccines — amounting to a total of $4,634.89.

The Health and Resources Service Administration (HRSA) vaccine injury claims report, updated monthly, shows one $2,019.55 payment for anaphylaxis and two payments — $1,582.65 and $1,032.69 — for myocarditis.

The payments were made through HRSA’s Countermeasures Injury Compensation Program (CICP).

The CICP was established under the Public Readiness and Emergency Preparedness (PREP) Act, which protects pharmaceutical companies from liability for injuries sustained from “countermeasures,” such as vaccines and medications, administered during a public health emergency.

Since 2010, when it approved its first claim, the program has compensated a total of 33 claims for vaccine injuries — but these are the first awards for COVID-19 vaccines.

“These long-awaited awards were overdue, highly anticipated and speculated upon,” said Kim Mack Rosenberg, acting general counsel for Children’s Health Defense (CHD). “What is remarkable is that less than $5,000 was paid — total. This is a tragedy that highlights the severe limitations of the program.”

CHD Acting President Laura Bono called the payouts for myocarditis “insulting,” given that mortality rates increase to 50% within five years of diagnosis.

Bono said:

“The CICP is a pathetic, government-run program that gives complete liability protection to the very industries profiting from the COVID vaccine or product. While victims linger with their injuries, paying out-of-pocket for expenses, or at worst die, the industries run to the bank.”

Since the start of the pandemic, people claiming injuries related to COVID-19 vaccines and other countermeasures submitted 11,425 requests for compensation.

Of those, only 19 have been declared eligible for compensation and are undergoing a “medical benefits review” to determine payment.

The anaphylaxis case had been pending medical benefits review since the fall of 2021, and the two myocarditis cases had been pending review since January.

During the medical benefits review, HRSA determines any costs remaining after insurance, workers’ comp, disability or other reimbursements or payments.

Wayne Rohde, an expert in vaccine injury compensation, wrote on his Substack that given the “18+ months to review previous medical benefits that may have been awarded to the injured party [the anaphylaxis case], this process tells me it was a major injury that resulted in very large medical bills.”

Myocarditis is a serious condition that also requires a lot of medical attention, Rohde said.

To date, there have been 1,541,275 reports of adverse events following COVID-19 vaccination submitted to the Vaccine Adverse Event Reporting System (VAERS).

How does vaccine injury compensation work? the VICP and CICP

HRSA, which operates under the U.S. Department of Health and Human Services (HHS), administers two vaccine injury compensation programs: the National Vaccine Injury Compensation Program (VICP) and the Countermeasures Injury Compensation Program (CICP).

The VICP is a special, no-fault tribunal housed within the U.S. Court of Federal Claims that handles injury claims for 16 common vaccines on the childhood vaccination schedule. To date, it has awarded more than $4 billion for medical bills, lost wages, lawyer fees, and pain and suffering to thousands of people for vaccine injuries.

The program does not currently cover COVID-19 vaccine injuries. Should COVID-19 vaccines be moved into the program, any injuries would be handled by the already overwhelmed VICP.

The CICP, the only program that covers COVID-19 vaccine injuries at this time, is even less equipped to deal with them, Rohde told The Defender.

“For COVID-19 vaccine-injured people, the CICP is the worst place, it’s the worst option,” Rohde said, “because it is not really a compensation program, it’s a reimbursement program for medical costs.”

The CICP allows individuals to claim compensation only for unreimbursed medical expenses — meaning those not fully reimbursed by insurance or government programs, such as Medicaid — for death and for lost wages up to $50,000.

According to the Centers for Disease Control and Prevention, under the CICP:

“Eligible individuals may be compensated for certain reasonable and necessary medical expenses and for lost employment income at the time of the injury. Death benefits may be paid to certain survivors of covered countermeasures recipients who have died as a direct result of the covered countermeasure injury.

“The U.S. Department of Health and Human Services is the payer of last resort. Therefore, payments are reduced by those of other third-party payers.”

“There’s no pain and suffering here, there’s nothing,” Rohde said.

Because the CICP reviews and resolves claims through an administrative rather than a judicial process, no details other than the amount of the payments have to be shared with the public.

“It’s designed to be very convoluted, very non-transparent,” Rohde said.

The CICP was known for its cumbersome claims process and low likelihood of success for claimants even before the pandemic. Since then, it has seen unsustainable growth.

According to HRSA’s numbers, of the 11,941 claims filed with the CICP since 2010, nearly 11,000 of them are still under review.

The HRSA budget for COVID-19 vaccine injury compensation will increase in fiscal year 2023 — from approximately $1 million to $5 million — and its budget for staffing and contractors will jump from $5 million to $9.5 million.

How would COVID vaccine injury compensation change under the VICP?

For vaccine injury claims to be covered under the VICP rather than the CICP, three requirements must be met:

  1. The vaccine needs to be recommended for routine administration for children and/or pregnant women.
  2. It needs to have an excise tax imposed upon it through the legislature.
  3. There needs to be a notice of coverage published in the federal record.

The COVID-19 vaccine was added to the childhood immunization schedule earlier this year — but the next two steps in the process have yet to be completed and public health officials have not indicated when this might happen.

The National Academies of Science, Engineering, and Medicine met for three days last month — behind closed doors, except for a two-hour public comment period — to review the epidemiological, clinical and biological evidence on adverse events associated with COVID-19 vaccines.

The committee will generate a report that will be used to add injuries to the federal Vaccine Injury Table, which lists known adverse events associated with existing vaccines.

This list helps the VICP and the CICP decide whether to compensate vaccine injury claims.

At the National Academies meeting, Professor Renee Gentry, director of the Vaccine Injury Litigation Clinic at The George Washington University Law School, told the committee the stakeholders that created the VICP — vaccine manufacturers, lawyers and parents — set it up to be petitioner-friendly, informal, generous and non-adversarial.

But instead, she said, HHS has been “unrelenting” in its opposition to recognizing vaccine injuries.

“I believe the VICP as it exists today would be unrecognizable to those original stakeholders,” she said.

*

Note to readers: Please click the share button above. Follow us on Instagram and Twitter and subscribe to our Telegram Channel. Feel free to repost and share widely Global Research articles.

Brenda Baletti Ph.D. is a reporter for The Defender. She wrote and taught about capitalism and politics for 10 years in the writing program at Duke University. She holds a Ph.D. in human geography from the University of North Carolina at Chapel Hill and a master’s from the University of Texas at Austin.

Featured image is from CHD


The Worldwide Corona Crisis, Global Coup d’Etat Against Humanity

by Michel Chossudovsky

Michel Chossudovsky reviews in detail how this insidious project “destroys people’s lives”. He provides a comprehensive analysis of everything you need to know about the “pandemic” — from the medical dimensions to the economic and social repercussions, political underpinnings, and mental and psychological impacts.

“My objective as an author is to inform people worldwide and refute the official narrative which has been used as a justification to destabilize the economic and social fabric of entire countries, followed by the imposition of the “deadly” COVID-19 “vaccine”. This crisis affects humanity in its entirety: almost 8 billion people. We stand in solidarity with our fellow human beings and our children worldwide. Truth is a powerful instrument.”

ISBN: 978-0-9879389-3-0,  Year: 2022,  PDF Ebook,  Pages: 164, 15 Chapters

Price: $11.50 Get yours for FREE! Click here to download.

We encourage you to support the eBook project by making a donation through Global Research’s DonorBox “Worldwide Corona Crisis” Campaign Page


Articles by: Dr. Brenda Baletti

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: [email protected]

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: [email protected]